Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 3/2014

01.09.2014 | Original Research

Patterns of Surveillance Following Curative Intent Therapy for Gastroesophageal Cancer

verfasst von: Renata D. Peixoto, Howard J. Lim, Haerin Kim, Ahmad Abdullah, Winson Y. Cheung

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Our aims were to examine surveillance strategies after curative treatment of early gastroesophageal (GE) cancer and to evaluate the impact of different approaches on outcomes.

Methods

A total of 292 patients with non-metastatic GE cancer who were referred to the BC Cancer Agency from 2001 to 2010 for curative intent treatment were analyzed. Surveillance practices were classified into the following: cohort 1 (discharge to general practitioner), cohort 2 (follow-up by oncologist with clinical assessments), cohort 3 (specialist follow-up with laboratory investigations), and cohort 4 (specialist follow-up with imaging or endoscopy). Outcomes were compared across cohorts using Kaplan–Meier methods and Cox regression.

Results

In total, median age was 63 years and 76 % were men. Eighty-nine (30 %), 18 (6 %), 32 (11 %), and 152 (53 %) patients were classified into cohorts 1 to 4, respectively. Patients with primary lesions involving the distal esophagus were more likely to undergo intensive surveillance which involved imaging studies and endoscopic procedures (p = 0.001). Individuals affected by specific histological subtypes, such as squamous cell carcinoma and the signet cell variant, and those whose disease were managed with definitive chemoradiotherapy without surgery were also more inclined to receive intensive follow-up (p = 0.008 and p = 0.001, respectively) There were no significant differences in overall (p = 0.34) or relapse-free survival (p = 0.59) among the different surveillance strategies, even after adjusting for measured prognostic factors.

Conclusion

In this population-based analysis, outcomes of GE cancer were comparable irrespective of surveillance strategy. Intensive follow-up with routine imaging and endoscopy may not be justified given the financial implications of these costly investigations.
Literatur
1.
Zurück zum Zitat Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2012) SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, 2013. Accessed 16 October 2013 Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (2012) SEER Cancer Statistics Review, 1975–2010, National Cancer Institute. Bethesda, MD. http://​seer.​cancer.​gov/​csr/​1975_​2010/​, based on November 2012 SEER data submission, posted to the SEER web site, 2013. Accessed 16 October 2013
2.
Zurück zum Zitat Journal of health and welfare statistic. Tokyo: Statistics and Information Department, Minister Secretariat, Ministry of Health and Welfare, 1996; 43:51 (in Japanese). No abstract available. Journal of health and welfare statistic. Tokyo: Statistics and Information Department, Minister Secretariat, Ministry of Health and Welfare, 1996; 43:51 (in Japanese). No abstract available.
5.
Zurück zum Zitat Nam JH, Choi IJ, Cho SJ, Kim CG, Jun JK, Choi KS, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer. 2012;118:4953–60. doi:10.1002/cncr.27495.PubMedCrossRef Nam JH, Choi IJ, Cho SJ, Kim CG, Jun JK, Choi KS, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer. 2012;118:4953–60. doi:10.​1002/​cncr.​27495.PubMedCrossRef
6.
Zurück zum Zitat Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309–15.PubMedCrossRef Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309–15.PubMedCrossRef
7.
Zurück zum Zitat Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.PubMedCrossRef Greenstein AJ, Litle VR, Swanson SJ, Divino CM, Packer S, Wisnivesky JP. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.PubMedCrossRef
8.
Zurück zum Zitat Park DJ, Lee HJ, Kim HH. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099–102.PubMedCrossRef Park DJ, Lee HJ, Kim HH. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099–102.PubMedCrossRef
9.
Zurück zum Zitat Dikken JL, Dassen AE, Lemmens VE, Putter H, Krijnen P, van der Geest L, et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. Eur J Cancer. 2012;48:1004–13. doi:10.1016/j.ejca.2012.02.064.PubMedCrossRef Dikken JL, Dassen AE, Lemmens VE, Putter H, Krijnen P, van der Geest L, et al. Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. Eur J Cancer. 2012;48:1004–13. doi:10.​1016/​j.​ejca.​2012.​02.​064.PubMedCrossRef
10.
Zurück zum Zitat Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92. doi:10.1016/S1470-2045(11)70142-5.PubMedCrossRef Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681–92. doi:10.​1016/​S1470-2045(11)70142-5.PubMedCrossRef
11.
Zurück zum Zitat Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer Resection. J Clin Oncol. 2012;30:2327–33. doi:10.1200/JCO.2011.36.7136.PubMedCrossRef Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer Resection. J Clin Oncol. 2012;30:2327–33. doi:10.​1200/​JCO.​2011.​36.​7136.PubMedCrossRef
12.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef
14.
Zurück zum Zitat Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30:3507–15.PubMedCrossRef Kunz PL, Gubens M, Fisher GA, Ford JM, Lichtensztajn DY, Clarke CA. Long-term survivors of gastric cancer: a California population-based study. J Clin Oncol. 2012;30:3507–15.PubMedCrossRef
15.
Zurück zum Zitat Desch CE, Benson 3rd AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512–9.PubMedCrossRef Desch CE, Benson 3rd AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512–9.PubMedCrossRef
16.
Zurück zum Zitat Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v70–7. doi:10.1093/annonc/mdq168.PubMedCrossRef Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v70–7. doi:10.​1093/​annonc/​mdq168.PubMedCrossRef
19.
Zurück zum Zitat Nakamura S, Suzuki S, Baba S. Resection of liver metastases of colorectal carcinoma. World J Surg. 1997;21:741–7.PubMedCrossRef Nakamura S, Suzuki S, Baba S. Resection of liver metastases of colorectal carcinoma. World J Surg. 1997;21:741–7.PubMedCrossRef
20.
Zurück zum Zitat Cady B, Stone MD, McDermott Jr WV, Jenkins RL, Bothe Jr A, Lavin PT, et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg. 1992;127:561–8.PubMedCrossRef Cady B, Stone MD, McDermott Jr WV, Jenkins RL, Bothe Jr A, Lavin PT, et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg. 1992;127:561–8.PubMedCrossRef
21.
Zurück zum Zitat Rolff HC, Calatayud D, Larsen PN, Wettergren A. Good results after repeated resection for colorectal liver metastases. Dan Med J. 2012;59:A4373.PubMed Rolff HC, Calatayud D, Larsen PN, Wettergren A. Good results after repeated resection for colorectal liver metastases. Dan Med J. 2012;59:A4373.PubMed
25.
Zurück zum Zitat Lacueva FJ, Calpena R, Medrano J, Compañ AF, Andrada E, Moltó M, et al. Follow-up of patients resected for gastric cancer. J Surg Oncol. 1995;60:174–9.PubMedCrossRef Lacueva FJ, Calpena R, Medrano J, Compañ AF, Andrada E, Moltó M, et al. Follow-up of patients resected for gastric cancer. J Surg Oncol. 1995;60:174–9.PubMedCrossRef
26.
31.
Zurück zum Zitat Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, et al. Prognostic web-based models for stage II and III colon cancer: a population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011;117:4155–65. doi:10.1002/cncr.26003.PubMedCentralPubMedCrossRef Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, et al. Prognostic web-based models for stage II and III colon cancer: a population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011;117:4155–65. doi:10.​1002/​cncr.​26003.PubMedCentralPubMedCrossRef
32.
34.
Zurück zum Zitat Eom BW, Ryu KW, Lee JH, Choi IJ, Kook MC, Cho SJ, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol. 2011;18:358–64. doi:10.1245/s10434-010-1395-3.PubMedCrossRef Eom BW, Ryu KW, Lee JH, Choi IJ, Kook MC, Cho SJ, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol. 2011;18:358–64. doi:10.​1245/​s10434-010-1395-3.PubMedCrossRef
36.
Zurück zum Zitat Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.PubMedCentralPubMedCrossRef Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 2002;324:813.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.PubMedCentralPubMedCrossRef Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;24, CD002200. Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;24, CD002200.
39.
Zurück zum Zitat Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.PubMedCrossRef Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003;10:898–902.PubMedCrossRef
40.
Zurück zum Zitat Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer—Is routine follow-up after gastrectomy worthwhile? Hepato-gastroenterology. 2000;47:1489–94.PubMed Bohner H, Zimmer T, Hopfenmuller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer—Is routine follow-up after gastrectomy worthwhile? Hepato-gastroenterology. 2000;47:1489–94.PubMed
41.
Zurück zum Zitat Takeyoshi I, Ohwada S, Ogawa T, Kawashima Y, Ohya T, Kawate S, et al. The resection of non-hepatic intraabdominal recurrence of gastric cancer. Hepato-gastroenterology. 2000;47:1479–81.PubMed Takeyoshi I, Ohwada S, Ogawa T, Kawashima Y, Ohya T, Kawate S, et al. The resection of non-hepatic intraabdominal recurrence of gastric cancer. Hepato-gastroenterology. 2000;47:1479–81.PubMed
42.
Zurück zum Zitat Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, et al. Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB (Oxford). 2006;8:89–92. doi:10.1080/13651820500472168.CrossRef Shirabe K, Wakiyama S, Gion T, Watanabe M, Miyazaki M, Yoshinaga K, et al. Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB (Oxford). 2006;8:89–92. doi:10.​1080/​1365182050047216​8.CrossRef
Metadaten
Titel
Patterns of Surveillance Following Curative Intent Therapy for Gastroesophageal Cancer
verfasst von
Renata D. Peixoto
Howard J. Lim
Haerin Kim
Ahmad Abdullah
Winson Y. Cheung
Publikationsdatum
01.09.2014
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 3/2014
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-014-9601-3

Weitere Artikel der Ausgabe 3/2014

Journal of Gastrointestinal Cancer 3/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.